BACKGROUND AND OBJECTIVES: Recently, we showed that soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels are diminished in hemodialysis patients and had additive effects with IL-6 on survival. Because sTWEAK plasma level has been associated with the presence of chronic kidney disease (CKD) and cardiovascular disease, we hypothesized that in patients with CKD, sTWEAK levels may relate to the increased prevalence of endothelial dysfunction that usually accompanies the decline of estimated GFR (eGFR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied 295 patients with different stages of nondiabetic CKD (52% male; age 47 +/- 12 yr), testing the association between sTWEAK plasma levels and CKD stage and the relationship between flow-mediated dilation (FMD) and sTWEAK concentrations. Fifty-five healthy volunteers (51% male; age 47 +/- 11 yr) served as matched control subjects. RESULTS: A gradual decrease in FMD was observed as eGFR decreased. Compared with healthy control subjects, sTWEAK plasma levels were diminished in all stages of CKD and correlated strongly with eGFR. FMD levels were associated with sTWEAK concentrations in univariate analysis. This association persisted after multivariate adjustment for eGFR levels, high-sensitivity C-reactive protein, diastolic BP, and sTWEAK, all of which were found to be significant and independent contributors to FMD. CONCLUSIONS: A decline in eGFR is accompanied by gradual reductions in sTWEAK plasma levels. Because sTWEAK strongly and independently correlated with FMD, our study suggests novel links between sTWEAK and endothelial dysfunction in patients with CKD.
BACKGROUND AND OBJECTIVES: Recently, we showed that soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels are diminished in hemodialysis patients and had additive effects with IL-6 on survival. Because sTWEAK plasma level has been associated with the presence of chronic kidney disease (CKD) and cardiovascular disease, we hypothesized that in patients with CKD, sTWEAK levels may relate to the increased prevalence of endothelial dysfunction that usually accompanies the decline of estimated GFR (eGFR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied 295 patients with different stages of nondiabetic CKD (52% male; age 47 +/- 12 yr), testing the association between sTWEAK plasma levels and CKD stage and the relationship between flow-mediated dilation (FMD) and sTWEAK concentrations. Fifty-five healthy volunteers (51% male; age 47 +/- 11 yr) served as matched control subjects. RESULTS: A gradual decrease in FMD was observed as eGFR decreased. Compared with healthy control subjects, sTWEAK plasma levels were diminished in all stages of CKD and correlated strongly with eGFR. FMD levels were associated with sTWEAK concentrations in univariate analysis. This association persisted after multivariate adjustment for eGFR levels, high-sensitivity C-reactive protein, diastolic BP, and sTWEAK, all of which were found to be significant and independent contributors to FMD. CONCLUSIONS: A decline in eGFR is accompanied by gradual reductions in sTWEAK plasma levels. Because sTWEAK strongly and independently correlated with FMD, our study suggests novel links between sTWEAK and endothelial dysfunction in patients with CKD.
Authors: L S Malatino; B Stancanelli; A Cataliotti; I Bellanuova; P Fatuzzo; F Rapisarda; D Leonardis; G Tripepi; F Mallamaci; C Zoccali Journal: J Intern Med Date: 2007-10 Impact factor: 8.989
Authors: Luis M Blanco-Colio; José L Martín-Ventura; José Tuñón; Tamara García-Camarero; José R Berrazueta; Jesús Egido Journal: Atherosclerosis Date: 2008-02-15 Impact factor: 5.162
Authors: Zeguo Zhao; Linda C Burkly; Sean Campbell; Noa Schwartz; Alberto Molano; Arpita Choudhury; Robert A Eisenberg; Jennifer S Michaelson; Chaim Putterman Journal: J Immunol Date: 2007-12-01 Impact factor: 5.422
Authors: Mohit Jain; Aniela Jakubowski; Lei Cui; Jianru Shi; Lihe Su; Michael Bauer; Jian Guan; Chee Chew Lim; Yoshiro Naito; Jeffrey S Thompson; Flora Sam; Christine Ambrose; Michael Parr; Thomas Crowell; John M Lincecum; Monica Z Wang; Yen-Ming Hsu; Timothy S Zheng; Jennifer S Michaelson; Ronglih Liao; Linda C Burkly Journal: Circulation Date: 2009-04-06 Impact factor: 29.690
Authors: Alberto Ortiz; Ana Belén Sanz; Begoña Muñoz García; Juan Antonio Moreno; Maria Dolores Sánchez Niño; Jose Luis Martín-Ventura; Jesús Egido; Luis Miguel Blanco-Colio Journal: Cytokine Growth Factor Rev Date: 2009-05-30 Impact factor: 7.638
Authors: Juan A Moreno; Begoña Muñoz-García; Jose L Martín-Ventura; Julio Madrigal-Matute; Josune Orbe; Jose A Páramo; Luis Ortega; Jesús Egido; Luis M Blanco-Colio Journal: Atherosclerosis Date: 2009-05-04 Impact factor: 5.162
Authors: Juan J Carrero; Alberto Ortiz; Abdul R Qureshi; Jose L Martín-Ventura; Peter Bárány; Olof Heimbürger; Belén Marrón; George Metry; Sunna Snaedal; Bengt Lindholm; Jesús Egido; Peter Stenvinkel; Luis M Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2008-10-22 Impact factor: 8.237
Authors: Carmen A Peralta; David R Jacobs; Ronit Katz; Joachim H Ix; Magdalena Madero; Daniel A Duprez; Mark J Sarnak; Michael H Criqui; Holly J Kramer; Walter Palmas; David Herrington; Michael G Shlipak Journal: Am J Kidney Dis Date: 2011-10-14 Impact factor: 8.860
Authors: Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2010-04-29 Impact factor: 8.237
Authors: Yago Leira; Pablo Ameijeira; Clara Domínguez; Esteban López-Arias; Paulo Ávila-Gómez; María Pérez-Mato; Tomás Sobrino; Francisco Campos; Francesco D'Aiuto; Rogelio Leira; Juan Blanco Journal: Clin Oral Investig Date: 2019-05-20 Impact factor: 3.573
Authors: Valvanera Fernández-Laso; Cristina Sastre; Jose M Valdivielso; Angels Betriu; Elvira Fernández; Jesús Egido; Jose L Martín-Ventura; Luis M Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2016-01-04 Impact factor: 8.237
Authors: Alper Azak; Mehmet Fatih Akdoğan; Nazım Denizli; Bülent Huddam; Gülay Koçak; Murat Gücün; Mustafa Adem Tatlısu; Recep Demirci; Bilal Yılmaz; Mehmet Dikeç; Murat Bakırtaş; Ibrahim Akdağ; Murat Duranay Journal: Int Urol Nephrol Date: 2013-09-17 Impact factor: 2.370
Authors: Ivan G Gomez; Allie M Roach; Naoki Nakagawa; Aldo Amatucci; Bryce G Johnson; Kadeshia Dunn; Mark C Kelly; Gamze Karaca; Timothy S Zheng; Suzanne Szak; Claire M Peppiatt-Wildman; Linda C Burkly; Jeremy S Duffield Journal: J Am Soc Nephrol Date: 2016-03-29 Impact factor: 10.121